Trevi Therapeutics, Inc. SEC filings TRVI
Trevi Therapeutics, Inc. has 537 filings in SEC EDGAR's recent list, going back to Dec 18, 2012. Its latest annual report, Form ARS, was filed on Apr 21, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 6, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Aug 15, 2023 | — |
| CORRESP | Letter to the SEC | Aug 14, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 5, 2023 | — |
| EFFECT | Filing | May 11, 2022 | — |
| CORRESP | Letter to the SEC | May 9, 2022 | — |
| UPLOAD | Letter from the SEC | May 6, 2022 | — |
| D | Filing | Apr 18, 2022 | — |
| EFFECT | Filing | Nov 16, 2021 | — |
| CORRESP | Letter to the SEC | Nov 12, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 10, 2021 | — |
| EFFECT | Filing | Oct 25, 2021 | — |
| D | Filing | Oct 21, 2021 | — |
| CORRESP | Letter to the SEC | Oct 21, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 21, 2021 | — |
| D | Filing | Oct 20, 2021 | — |
| RW | Filing | Oct 8, 2021 | — |
| EFFECT | Filing | Jul 14, 2021 | — |
| CORRESP | Letter to the SEC | Jul 12, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 9, 2021 | — |
| EFFECT | Filing | Jul 2, 2020 | — |
| UPLOAD | Letter from the SEC | Jun 30, 2020 | — |
| CORRESP | Letter to the SEC | Jun 30, 2020 | — |
| EFFECT | Filing | May 7, 2019 | — |
| UPLOAD | Letter from the SEC | May 7, 2019 | — |
| CORRESP | Letter to the SEC | May 7, 2019 | — |
| CERT | Filing | Apr 30, 2019 | — |
| CORRESP | Letter to the SEC | Apr 29, 2019 | — |
| CORRESP | Letter to the SEC | Apr 29, 2019 | — |
| 8-A12B | Filing | Apr 29, 2019 | — |
| CORRESP | Letter to the SEC | Apr 11, 2019 | — |
| DRS/A | Filing | Feb 21, 2019 | — |
| DRSLTR | Filing | Feb 20, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 15, 2019 | — |
| DRSLTR | Filing | Dec 21, 2018 | — |
| DRS/A | Filing | Dec 21, 2018 | — |
| UPLOAD | Letter from the SEC | Dec 18, 2018 | — |
| DRS | Filing | Nov 19, 2018 | — |
| D/A | Filing | Sep 5, 2018 | — |
| D | Filing | Jul 24, 2017 | — |
| D | Filing | Dec 18, 2012 | — |
Showing 40 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TRVI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1563880
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.